What Is KLOW Peptide? The 4-Peptide Blend Explained

KLOW is a research-context name for one vial that holds four peptides: GHK-Cu, KPV, BPC-157, and TB-500. Each one is a known peptide with its own research. KLOW is the name sellers use when all four come premixed.

The most common version is an 80 mg vial with 50 mg of GHK-Cu and 10 mg each of KPV, BPC-157, and TB-500. Some sellers use a different ratio, so read the label. KLOW is sold as a research compound. The FDA hasn't approved it, and no published trial has tested the four peptides together.

The letters don't stand for anything official. Most people read KLOW as a twist on GLOW, an older blend of GHK-Cu, BPC-157, and TB-500. The K is usually taken to mean KPV, the peptide KLOW adds. Since nobody owns the name, two sellers can print "KLOW" on vials with different contents. Check the label and the test report before you trust a product.

You'll also see it called "KLOW 80," "KLOW blend," or "KLOW stack." They all mean the same four-peptide mix. The 80 is the total milligrams in the vial.

Each peptide in KLOW comes from a separate line of research, and the evidence behind them is uneven. GHK-Cu makes up most of the vial. The other three share the rest equally.

GHK-Cu is a small peptide made of three amino acids (glycine, histidine, and lysine) bound to copper. It's found naturally in human blood, and levels drop with age. Much of the research comes from Loren Pickart's lab. Those studies report more collagen and elastin, antioxidant effects, and shifts in the activity of thousands of genes in cell data. Because GHK-Cu is most of the vial, mixed KLOW often looks light blue from the copper.

KPV is three amino acids (lysine, proline, and valine) from the end of a hormone called alpha-MSH. In mouse studies of colitis, KPV got into gut cells through a transporter called PepT1. Inside the cells, it turned down NF-κB, a protein that switches on inflammation. Of the four peptides in KLOW, KPV is the one picked for inflammation. The other three are mostly studied for repair.

BPC-157 is a chain of 15 amino acids based on a protein found in stomach juice. Animal studies report faster tendon and ligament healing, new blood vessel growth, and protection of the gut lining. Human data is scarce. A 2025 review counted 36 studies, and only one of them was in people.

TB-500 is a lab-made peptide based on thymosin beta-4. Thymosin beta-4 binds actin, the protein cells use to move around. Researchers study it for helping cells crawl into a wound and close it. Most human trials tested full-length thymosin beta-4, which is a bigger molecule than the TB-500 in research vials. Labels vary too, so "TB-500" on one vial may not match "TB-500" on another.

The KLOW benefits people talk about are research-context interests and community reports. Each one traces back to studies of a single peptide. None has been shown for the blend.

Lots of people search for KLOW results and before-and-after photos. There's no way to check those photos. They rarely name the product, list what else changed, or show that the vial matched its label, so read them as personal stories. For how long the single-peptide studies ran, see the KLOW cycle length guide.

The idea behind KLOW is layering. Each peptide is studied in a different step of tissue repair, and the hope is that four steps together cover more than one. People usually describe the layers like this:

GLOW already covers rebuilding, blood flow, and cell movement. KLOW keeps those three and adds KPV. The GLOW peptides calm inflammation only as a side effect of repair, while KPV goes after the inflammation signal itself. That's why people who pick KLOW over GLOW usually care about inflammation or gut health. Without that interest, the two blends are almost the same.

GHK-Cu is 62.5% of a standard KLOW vial. KLOW kept that share from GLOW, where GHK-Cu was already the biggest part. So any amount drawn from a KLOW vial is mostly GHK-Cu, and there's no way to change the other three on their own. Separate vials avoid that problem but take more work.

There's no direct evidence for KLOW. We couldn't find a peer-reviewed human or animal study of the four-peptide combination, and ClinicalTrials.gov lists no trial of it. Every claim about KLOW comes from separate studies of each peptide.

Thymosin beta-4 has the best human data of the four. Treadwell and colleagues (2012) reported two Phase 2 trials in people with leg ulcers from poor circulation and with pressure ulcers. Wounds healed faster in the patients who responded. A 2012 review by Goldstein and colleagues explains how it may work: it binds actin, helps cells move, and helps keep cells alive. These trials used full-length thymosin beta-4 rather than TB-500, and none led to an FDA-approved drug.

BPC-157 has dozens of animal studies and very few human ones. A 2025 systematic review by Vasireddi and colleagues found 35 animal or lab studies and 1 clinical study. A 2025 review by McGuire and colleagues came to a similar view and called BPC-157 investigational, meaning it's still being tested. The few human reports are small pilots without control groups. One IV safety pilot (Lee and Burgess, 2025) had two people in it.

GHK-Cu has decades of lab research. Pickart and Margolina's 2018 review reports shifts in thousands of human genes in a cell-line database, and KLOW marketing often quotes that number. Gene changes in cells don't show that GHK-Cu does anything in a living person, though. Most human GHK-Cu studies tested skin creams. Few looked at the injected form in KLOW vials.

The KPV research we found is all in mice and cells. Kannengiesser and colleagues (2008) found that it lowered inflammation in two mouse models of colitis. Dalmasso and colleagues (2008) showed that it enters gut cells through PepT1. We found no published human trial of KPV.

These three blends build on each other. Wolverine has two peptides, GLOW adds a third, and KLOW adds a fourth. KLOW and GLOW differ by one ingredient, KPV.

GLOW and KLOW have the same amounts of GHK-Cu, BPC-157, and TB-500. KLOW adds 10 mg of KPV. For skin, collagen, and tissue repair research, GLOW covers the same ground. KLOW makes more sense when inflammation or gut health is part of the research question. Neither blend has been tested in a trial, so no study shows that one beats the other. See the GLOW stack guide for more on GLOW.

Wolverine is the two-peptide base of BPC-157 and TB-500. It's aimed at soft-tissue and tendon research and leaves out GHK-Cu and KPV. KLOW covers more ground. It also has more ingredients that can go wrong in manufacturing, and more possible causes if a side effect shows up. The Wolverine stack guide covers the simpler blend.

Some people skip the premix and buy each peptide alone. With separate vials, each peptide can be changed or dropped, and it's easier to tell which one caused a side effect. A KLOW vial is simpler and often costs less, but every draw gives all four peptides in the same fixed ratio.

No one has published a safety study of the KLOW blend. What we know comes from research on single peptides and from user reports. For a longer list of reported side effects and who is usually told to avoid KLOW, see the side effects section of the KLOW dosing guide.

No. The FDA hasn't approved KLOW or any of its four peptides for use in people. Their status for compounding pharmacies has changed several times since 2023:

BPC-157 and TB-500 are also on the World Anti-Doping Agency's S0 list of unapproved substances, so they're banned in tested sports. KLOW sold online carries a "research use only" label, which means it isn't meant or approved for use in people.

People search Reddit and forums for KLOW experiences a lot. The themes here come up most often in those threads. They're anecdotal: nobody verified them, there's no comparison group, and many posters changed other things at the same time or used products of unknown quality.